nitroglycerin transdermal (Rx)

Brand and Other Names:NitroDur, Minitran, more...Deponit, Transdermal Nitroglycerin, Nitrocine, glyceryl trinitrate transdermal
  • Print

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

patch

  • 0.1mg/hr
  • 0.2mg/hr
  • 0.3mg/hr
  • 0.4mg/hr
  • 0.6mg/hr
  • 0.8mg/hr

Angina Pectoris

1 Patch qDay; Start with smallest unit in series & titrate

Patches may be applied to any skin surface, except on extremities below the knees or elbows

Nitrate-free period of 10-12 hours duration (overnight) needed to prevent tolerance

Minitran 0.1, 0.2, 0.4, 0.6 mg/hr

Nitro-Dur 0.1, 0.2, 0.3, 0.4, 0.6, 0.8 mg/hr

Transdermal-nitroglyderin 0.1, 0.2, 0.4, 0.6 mg/hr

Not FDA approved in children

Angina pectoris

1 Patch qDay; Start with smallest unit in series & titrate

Patches may be applied to any skin surface, except on extremities below the knees or elbows

Nitrate-free period of 10-12 hours duration (overnight) needed to prevent tolerance

Minitran 0.1, 0.2, 0.4, 0.6 mg/hr

Nitro-Dur 0.1, 0.2, 0.3, 0.4, 0.6, 0.8 mg/hr

Transdermal-nitroglyderin 0.1, 0.2, 0.4, 0.6 mg/hr

Next:

Interactions

Interaction Checker

and nitroglycerin transdermal

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (12)

            • avanafil

              nitroglycerin transdermal, avanafil. Mechanism: additive vasodilation. Contraindicated. Potentially fatal hypotension.

            • bromocriptine

              bromocriptine decreases effects of nitroglycerin transdermal by pharmacodynamic antagonism. Contraindicated.

            • cabergoline

              cabergoline decreases effects of nitroglycerin transdermal by pharmacodynamic antagonism. Contraindicated.

            • dihydroergotamine

              dihydroergotamine decreases effects of nitroglycerin transdermal by pharmacodynamic antagonism. Contraindicated.

            • dihydroergotamine intranasal

              dihydroergotamine intranasal decreases effects of nitroglycerin transdermal by pharmacodynamic antagonism. Contraindicated.

            • ergoloid mesylates

              ergoloid mesylates decreases effects of nitroglycerin transdermal by pharmacodynamic antagonism. Contraindicated.

            • ergotamine

              ergotamine decreases effects of nitroglycerin transdermal by pharmacodynamic antagonism. Contraindicated.

            • methylergonovine

              methylergonovine decreases effects of nitroglycerin transdermal by pharmacodynamic antagonism. Contraindicated.

            • riociguat

              nitroglycerin transdermal, riociguat. Either increases effects of the other by additive vasodilation. Contraindicated. Coadministration of nitrates or nitric oxide donors is contraindicated due to risk of hypotension.

            • sildenafil

              nitroglycerin transdermal, sildenafil. Mechanism: additive vasodilation. Contraindicated. Potentially fatal hypotension.

            • tadalafil

              nitroglycerin transdermal, tadalafil. Mechanism: additive vasodilation. Contraindicated. Potentially fatal hypotension.

            • vardenafil

              nitroglycerin transdermal, vardenafil. Mechanism: additive vasodilation. Contraindicated. Potentially fatal hypotension.

            Serious - Use Alternative (5)

            • cabergoline

              nitroglycerin transdermal increases effects of cabergoline by decreasing metabolism. Avoid or Use Alternate Drug. Risk of increased SBP, angina pectoris.

            • ergoloid mesylates

              nitroglycerin transdermal increases effects of ergoloid mesylates by decreasing metabolism. Avoid or Use Alternate Drug. Risk of increased SBP, angina pectoris.

            • ergotamine

              nitroglycerin transdermal increases effects of ergotamine by decreasing metabolism. Avoid or Use Alternate Drug. Risk of increased SBP, angina pectoris.

            • lofexidine

              lofexidine, nitroglycerin transdermal. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration with other drugs that decrease pulse or blood pressure to mitigate risk of excessive bradycardia and hypotension.

            • methylergonovine

              nitroglycerin transdermal increases effects of methylergonovine by decreasing metabolism. Avoid or Use Alternate Drug. Risk of increased SBP, angina pectoris.

            Monitor Closely (6)

            • arginine

              nitroglycerin transdermal, arginine. Mechanism: additive vasodilation. Use Caution/Monitor. Possible hypotension.

            • benazepril

              nitroglycerin transdermal, benazepril. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs lower blood pressure. Monitor blood pressure.

            • bretylium

              nitroglycerin transdermal, bretylium. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Each drug may cause hypotension.

            • bupivacaine implant

              nitroglycerin transdermal, bupivacaine implant. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Local anesthetics may increase the risk of developing methemoglobinemia when concurrently exposed to drugs that also cause methemoglobinemia.

            • dapsone topical

              nitroglycerin transdermal increases toxicity of dapsone topical by altering metabolism. Modify Therapy/Monitor Closely. May induce methemoglobinemia.

            • tetracaine

              tetracaine, nitroglycerin transdermal. Other (see comment). Use Caution/Monitor. Comment: Monitor for signs of methemoglobinemia when methemoglobin-inducing drugs are coadministered.

            Minor (3)

            • acetylcysteine

              acetylcysteine increases effects of nitroglycerin transdermal by Other (see comment). Minor/Significance Unknown. Comment: Acetylcysteine may enhance vasodilatory effects of nitroglycerin.

            • acetylcysteine (Antidote)

              acetylcysteine (Antidote) increases effects of nitroglycerin transdermal by Other (see comment). Minor/Significance Unknown. Comment: Acetylcysteine may enhance vasodilatory effects of nitroglycerin.

            • ethanol

              nitroglycerin transdermal, ethanol. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible hypotension.

            Previous
            Next:

            Adverse Effects

            Common

            Headache

            Hypotension

            Tachycardia

            Dizziness

            Lightheadedness

            Blurred vision

            Flushing

            N/V

            Nervousness

            Xerostomia

            Topical allergic reactions

            Serious

            Methemoglobinemia (rare)

            Syncope

            Prolonged bleeding time

            Exfoliative dermatitis

            Unstable angina

            Rebound hypertension

            Thrombocytopenia

            Previous
            Next:

            Warnings

            Contraindications

            Hypersensitivity to organic nitrates or adhesives

            Recent use (within several days) of PDE-5 inhibitors (eg, avanafil, sildenafil, tadalafil, or vardenafil) may cause dangerously low hypotension; the time course of the interaction appears to be related to the PDE-5 inhibitor half-life

            Concomitant administration with guanylate stimulator riociguat (may cause hypotension)

            Cautions

            Use caution in alcohol use, increased ICP (eg, head trauma, cerebral hemorrhage-potential contraindication), hyperthyroidism, hypertrophic cardiomyopathy, increased IOP, postural hypotension, volume depletion, low systolic BP

            Benefits of transdermal nitroglycerin in patients with acute myocardial infarction or congestive heart failure not established; if one elects to use nitroglycerin in these conditions, careful clinical or hemodynamic monitoring must be used to avoid hazards of hypotension and tachycardia

            Transdermal system should not be used to treat acute angina attacks

            Severe hypotension, particularly with upright posture, may occur with even small doses of nitroglycerin, particularly in the elderly; use caution

            Nitrate therapy may aggravate angina caused by hypertrophic cardiomyopathy, particularly in the elderly

            A cardioverter/defibrillator should not be discharged through a paddle electrode that overlies a patch; the arcing that may be seen in this situation is harmless in itself but may be associated with local current concentration that can cause damage to paddles and burns to patient

            Discarded patches should be kept out of reach of children and pets

            Chest pain, acute myocardial infarction, and even sudden death reported during temporary withdrawal of nitrates from industrial workers with long-term exposure to unknown high doses of organic nitrates, demonstrating the existence of true physical dependence

            Use with caution in elderly patients who may be volume-depleted, are on multiple medications, or who, for whatever reason, are already hypotensive; hypotension induced by nitroglycerin may be accompanied by paradoxical bradycardia and increased angina pectoris; elderly patients may also be more susceptible to hypotension and may be at greater risk of falling at therapeutic doses

            Drug interaction overview

            • Amplification of vasodilatory effects of the patch by phosphodiesterase inhibitors, eg, sildenafil can result in severe hypotension; the time course and dose dependence of this interaction have not been studied; appropriate supportive care has not been studied, but seems reasonable to treat this as a nitrate overdose, with elevation of extremities and with central volume expansion
            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy Category: C

            Lactation: not known whether the drug crosses into breast milk, use caution

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.

            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Organic nitrate which causes systemic venodilation, decreasing preload

            Cellular mechanism: nitrate enters vascular smooth muscle & converted to nitric oxide (NO) leading to activation of cGMP & vasodilation

            Pharmacokinetics

            Half-Life: 12-33 min

            Onset: 60 min

            Duration: 10-12 hr

            Bioavailability: 75%

            Protein Bound: 60%

            Vd: 3 L/kg

            Metabolism: Mainly in liver, extrahepatic sites: vascular wall, RBC

            Metabolites: 1,3-glyceryl dinitrate, 1,2-glyceryl dinitrate, and glyceryl mononitrate (inactive)

            Clearance: 5.5-11 L/min

            Excretion: Urine

            Dialyzable: No

            Previous
            Next:

            Images

            BRAND FORM. UNIT PRICE PILL IMAGE
            Nitro-Bid transdermal
            -
            2 % ointment
            Nitro-Bid transdermal
            -
            2 % ointment
            Nitro-Bid transdermal
            -
            2 % ointment
            nitroglycerin sublingual
            -
            0.4 mg tablet
            nitroglycerin sublingual
            -
            0.4 mg tablet
            nitroglycerin sublingual
            -
            0.3 mg tablet
            nitroglycerin sublingual
            -
            0.6 mg tablet
            nitroglycerin sublingual
            -
            0.6 mg tablet
            nitroglycerin sublingual
            -
            0.6 mg tablet
            nitroglycerin sublingual
            -
            0.3 mg tablet
            nitroglycerin sublingual
            -
            0.4 mg tablet
            nitroglycerin sublingual
            -
            0.4 mg tablet
            nitroglycerin sublingual
            -
            0.4 mg tablet
            nitroglycerin sublingual
            -
            0.4 mg tablet
            nitroglycerin intravenous
            -
            50 mg/10 mL (5 mg/mL) vial
            Nitro-Dur transdermal
            -
            0.3 mg/hr transdermal system
            Nitro-Dur transdermal
            -
            0.8 mg/hr transdermal system
            nitroglycerin transdermal
            -
            0.6 mg/hr transdermal system
            nitroglycerin transdermal
            -
            0.4 mg/hr transdermal system
            nitroglycerin transdermal
            -
            0.4 mg/hr transdermal system
            nitroglycerin transdermal
            -
            0.2 mg/hr transdermal system
            nitroglycerin transdermal
            -
            0.1 mg/hr transdermal system
            nitroglycerin transdermal
            -
            0.6 mg/hr transdermal system
            nitroglycerin transdermal
            -
            0.4 mg/hr transdermal system
            nitroglycerin transdermal
            -
            0.2 mg/hr transdermal system
            nitroglycerin transdermal
            -
            0.4 mg/hr transdermal system
            nitroglycerin transdermal
            -
            0.6 mg/hr transdermal system
            nitroglycerin transdermal
            -
            0.2 mg/hr transdermal system
            nitroglycerin transdermal
            -
            0.2 mg/hr transdermal system
            nitroglycerin transdermal
            -
            0.2 mg/hr transdermal system
            nitroglycerin transdermal
            -
            0.4 mg/hr transdermal system
            nitroglycerin transdermal
            -
            0.6 mg/hr transdermal system
            nitroglycerin transdermal
            -
            0.4 mg/hr transdermal system
            nitroglycerin transdermal
            -
            0.2 mg/hr transdermal system
            nitroglycerin transdermal
            -
            0.1 mg/hr transdermal system
            Nitrostat sublingual
            -
            0.4 mg tablet
            Nitrostat sublingual
            -
            0.6 mg tablet
            Nitrostat sublingual
            -
            0.4 mg tablet
            Nitrostat sublingual
            -
            0.3 mg tablet
            Nitro-Time oral
            -
            9 mg capsule
            Nitro-Time oral
            -
            6.5 mg capsule
            Nitro-Time oral
            -
            2.5 mg capsule
            GoNitro sublingual
            -
            400 mcg powder
            GoNitro sublingual
            -
            400 mcg powder
            nitroglycerin translingual
            -
            400 mcg/spray solution
            nitroglycerin translingual
            -
            400 mcg/spray solution
            nitroglycerin translingual
            -
            400 mcg/spray solution
            nitroglycerin translingual
            -
            400 mcg/spray solution
            nitroglycerin oral
            -
            9 mg capsule
            nitroglycerin oral
            -
            6.5 mg capsule
            nitroglycerin oral
            -
            2.5 mg capsule
            nitroglycerin oral
            -
            2.5 mg capsule
            Rectiv rectal
            -
            0.4 % (w/w) ointment
            Nitrolingual translingual
            -
            400 mcg/spray solution
            Nitrolingual translingual
            -
            400 mcg/spray solution
            Nitromist translingual
            -
            400 mcg/spray aerosol

            Copyright © 2010 First DataBank, Inc.

            Previous
            Next:

            Patient Handout

            Select a drug:
            Patient Education
            nitroglycerin transdermal

            NITROGLYCERIN OINTMENT - TRANSDERMAL

            (NYE-troe-GLIS-er-in)

            COMMON BRAND NAME(S): Nitro-Bid

            USES: Nitroglycerin ointment is used to prevent chest pain (angina) in people with a certain heart condition (coronary artery disease). This medication belongs to a class of drugs known as nitrates. Angina occurs when the heart muscle is not getting enough blood. This drug works by relaxing and widening blood vessels so blood can flow more easily to the heart.This medication will not relieve chest pain once it occurs. It is also not intended to be used just before physical activities (such as exercise, sexual activity) to prevent chest pain. Other medications may be needed in these situations. Consult your doctor for more details.

            HOW TO USE: Read the Patient Information Leaflet available from your pharmacist. Consult your doctor or pharmacist if you have any questions.Apply this medication as directed by your doctor. Avoid touching the ointment with your fingers. Carefully squeeze out your dose onto a paper dose-measuring applicator. These applicators are supplied with the medication. Place the paper applicator with the ointment side down onto a dry, hairless area of skin, usually on the chest. Do not rub the ointment into the skin. Using the paper, lightly spread the ointment to cover an area of a size directed by your doctor. Tape the paper applicator into place and cover with plastic wrap to avoid staining your clothing. Wash your hands after applying and removing the medication.Remember to use a different area for each application. It is important to apply this medication at the same times each day. Do not change the dosing times unless directed by your doctor. The dosage is based on your medical condition and response to treatment. Remove the medication daily as directed by your doctor.Use this medication regularly to get the most benefit from it. Do not stop using this medication without consulting your doctor. Some conditions may become worse when the drug is suddenly stopped. Your dose may need to be gradually decreased.Although unlikely, when this medication is used for a long time, it may not work as well and may require different dosing. Tell your doctor if this medication stops working well (for example, you have worsening chest pain or it occurs more often).

            SIDE EFFECTS: Headache, dizziness, lightheadedness, nausea, and flushing may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.Headache is often a sign that this medication is working. Your doctor may recommend treating headaches with an over-the-counter pain reliever (such as acetaminophen, aspirin). If the headaches continue or become severe, tell your doctor promptly.To reduce the risk of dizziness and lightheadedness, get up slowly when rising from a sitting or lying position.Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.Tell your doctor right away if you have any serious side effects, including: fainting, fast/irregular/pounding heartbeat.A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

            PRECAUTIONS: Before using this medication, tell your doctor or pharmacist if you are allergic to it; or to similar drugs (such as isosorbide mononitrate); or to nitrites; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: recent head injury, anemia, low blood pressure, dehydration, other heart problems (such as recent heart attack).This drug may make you dizzy. Alcohol or marijuana (cannabis) can make you more dizzy. Do not drive, use machinery, or do anything that needs alertness until you can do it safely. Limit alcoholic beverages. Talk to your doctor if you are using marijuana (cannabis).Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).Older adults may be more sensitive to the side effects of this medication, especially dizziness and lightheadedness which could increase the risk of falls.During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.It is unknown if this medication passes into breast milk or if it may harm a nursing infant. Consult your doctor before breast-feeding.

            DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.Some products that may interact with this drug include: drugs used to treat erectile dysfunction-ED or pulmonary hypertension (such as sildenafil, tadalafil), certain drugs to treat migraine headaches (ergot alkaloids such as ergotamine), riociguat.This medication may interfere with certain laboratory tests (including blood cholesterol levels), possibly causing false test results. Make sure laboratory personnel and all your doctors know you use this drug.

            OVERDOSE: This medicine may be harmful if swallowed. If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include: slow heartbeat, vision changes, severe nausea/vomiting, sweating, cold/clammy skin, bluish fingers/toes/lips.

            NOTES: Do not share this medication with others.Laboratory and/or medical tests (such as blood pressure monitoring) should be performed periodically to monitor your progress or check for side effects. Consult your doctor for more details.Lifestyle changes such as dietary changes, exercise, and stopping smoking may help this drug work better. Talk to your doctor or pharmacist about lifestyle changes that might benefit you.

            MISSED DOSE: If you miss a dose, apply it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Use your next dose at the regular time. Do not double the dose to catch up.

            STORAGE: Store at room temperature away from light and moisture. Close the tube tightly right after each use. Do not store in the bathroom. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.

            MEDICAL ALERT: Your condition can cause complications in a medical emergency. For information about enrolling in MedicAlert, call 1-888-633-4298 (US) or 1-800-668-1507 (Canada).

            Information last revised April 2022. Copyright(c) 2022 First Databank, Inc.

            IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.